Replimune Group, Inc. (NASDAQ:REPL – Get Rating) CFO Jean M. Franchi sold 11,351 shares of Replimune Group stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $18.05, for a total transaction of $204,885.55. Following the completion of the transaction, the chief financial officer now directly owns 128,748 shares of the company’s stock, valued at approximately $2,323,901.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Replimune Group Stock Performance
Shares of REPL stock opened at $19.58 on Friday. The company has a quick ratio of 23.58, a current ratio of 23.58 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $18.02 and a 200 day simple moving average of $21.87. Replimune Group, Inc. has a 52 week low of $13.54 and a 52 week high of $29.52.
Institutional Trading of Replimune Group
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Replimune Group by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,495,616 shares of the company’s stock worth $97,054,000 after buying an additional 430,872 shares during the period. BlackRock Inc. boosted its holdings in shares of Replimune Group by 20.3% during the 1st quarter. BlackRock Inc. now owns 3,622,104 shares of the company’s stock worth $63,966,000 after buying an additional 611,552 shares during the period. State Street Corp raised its stake in Replimune Group by 96.3% in the 1st quarter. State Street Corp now owns 2,904,354 shares of the company’s stock worth $51,291,000 after purchasing an additional 1,424,810 shares in the last quarter. BVF Inc. IL raised its stake in Replimune Group by 40.7% in the 1st quarter. BVF Inc. IL now owns 2,143,036 shares of the company’s stock worth $37,846,000 after purchasing an additional 620,407 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Replimune Group by 5.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,848,167 shares of the company’s stock worth $31,919,000 after purchasing an additional 89,618 shares in the last quarter. Institutional investors own 87.83% of the company’s stock.
Analyst Upgrades and Downgrades
Replimune Group Company Profile
Replimune Group, Inc is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm’s Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response.
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.